Tom Brazier

Partner, Solicitor
London

Tom is a patent litigator and partner within the litigation team, and joined EIP from a UK Magic Circle law firm in 2018.

During 10 years in private practice, Tom has experience of proceedings in the English High Court, Court of Appeal and Supreme Court. Tom acted in two of the most important patent cases in the last decade: for Warner-Lambert, a Pfizer group company, against Actavis and Mylan in relation to second medical use patent litigation in respect of its pain drug, Lyrica® (pregabalin), and for Unwired Planet and Conversant in proceedings against Huawei and ZTE on the issue of FRAND in the context of Standard- Essential Patents (SEPs) in the field of telecommunications.

Tom has extensive life sciences experience, having also represented Warner-Lambert against Sandoz in securing injunctive relief to prevent the launch of a full label generic version of Lyrica®, Biomet against Heraeus in trade secrets litigation concerning bone cements and acting for a leading pharmaceutical company on its global patent enforcement strategy in relation to one of its blockbuster drugs.

In the telecommunications sector, Tom acted for Optis in its successful enforcement of EP (UK) 2,229,744 against Apple. Tom currently acts for IP Bridge in SEP proceedings against Huawei. In his telecoms patent litigation practice, Tom has a particular interest and expertise in FRAND-related issues, including issues of jurisdiction and anti-suit relief.

Tom studied Modern Languages at the University of Oxford before starting his law career. He holds a Graduate Diploma in Law from BPP Law School, completed the Legal Practice Course at the College of Law, and has a Postgraduate Diploma in Intellectual Property Law from the University of Oxford.

Experience

  • Acting for IP Bridge in SEP proceedings against Huawei.
  • Acting for Optis in its successful enforcement of EP (UK) 2,229,744 against Apple. (link)
  • Acting for Unwired Planet and Conversant Wireless in successful Supreme Court proceedings against Huawei (and ZTE for Conversant) on the issue of FRAND in the context of Standard Essential Patents (SEPs) in the field of telecommunication. (link)
  • Acting for Warner-Lambert, a Pfizer group company, against Actavis and Mylan in relation to second medical use patent litigation in respect of its pain drug, Lyrica® (pregabalin).
  • Acting for Warner-Lambert against Sandoz in securing injunctive relief to prevent the launch of a full label generic version of Lyrica® (pregabalin).
  • Acting for Biomet against Heraeus in trade secrets litigation concerning bone cements.
  • Acting for a leading pharmaceutical company on its global patent enforcement strategy in relation to one of its blockbuster drugs.

Published articles

  • August 2022
    IAM, Anti-suit relief may be about to get a second wind in UK FRAND cases (link)
  • April 2021
    IAM, Why comparable licences are key in the biggest SEP battles (link)

Education and qualifications

  • 2012 — 2013
    Postgraduate Diploma in Intellectual Property Law, University of Oxford
  • 2009 — 2010
    Legal Practice Course, College of Law
  • 2008 — 2009
    Graduate Diploma in Law, BPP Law School
  • 2004 — 2008
    MA Modern Languages (Russian and Spanish), University of Oxford

Career history

  • 2022 — present
    Partner, EIP
  • 2018 — 2022
    Managing Associate, EIP
  • 2012 — 2018
    Associate, Allen & Overy LLP
  • 2010 — 2012
    Trainee Solicitor, Allen & Overy LLP

Awards and recognition

  • Ranked as 'Notable practitioner', IP Stars 2022 (link)
  • Ranked as "Rising Star", IP Stars 2021 (link)
  • Ranked as "Rising Star", IP Stars 2020
  • Ranked as "Rising star", Legal 500 2020

Languages spoken

  • French (Fluent)
  • Spanish (Proficient)
  • Russian (Proficient)

Speaking engagements

  • January 2022
    American Bar Association Webinar, Anti-Suit Injunctions, Anti-Anti-Suit Injunctions, etc, in Extraterritorial Litigation